the identification of sites where rna-binding proteins (rnaBps) interact with target rnas opens the door to understanding the vast complexity of rna regulation. uV cross-linking and immunoprecipitation (clIp) is a transformative technology in which rnas purified from in vivo cross-linked rna-protein complexes are sequenced to reveal footprints of rnaBp:rna contacts. clIp combined with high-throughput sequencing (HIts-clIp) is a generalizable strategy to produce transcriptome-wide maps of rna binding with higher accuracy and resolution than standard rna immunoprecipitation (rIp) profiling or purely computational approaches. the application of clIp to argonaute proteins has expanded the utility of this approach to mapping binding sites for micrornas and other small regulatory rnas. Finally, recent advances in data analysis take advantage of cross-link-induced mutation sites (cIMs) to refine rna-binding maps to single-nucleotide resolution. once Ip conditions are established, HIts-clIp takes ~8 d to prepare rna for sequencing. established pipelines for data analysis, including those for cIMs, take 3-4 d. Development of the protocol CLIP grew out of two main frustrations with traditional approaches to studying RNA regulation in the course of studies of the neuron-specific RNABP Nova. First were constraints on the ability to study RNA-protein interactions in an unbiased, genomewide manner. Early efforts to define Nova RNA targets used splicing-sensitive exon junction microarrays to probe RNA from the brains of wild-type and Nova-null mice. These studies showed Nova-dependent splicing regulation of a biologically coherent set of presynaptic and postsynaptic proteins 12,13 . However, these results also highlighted a second difficulty, in that direct Nova targets could not be distinguished definitively from downstream or indirect effects of Nova loss of function. Although the presence of Nova's binding motif suggested that a substantial number of targets were direct 14 , the indirect nature of the study and the low complexity of Nova's binding motif (YCAY) prevented highconfidence conclusions.
IntroDuctIon
HITS-CLIP experiments provide the state-of-the-art means of identifying RNA-binding sites for any RNABP of interest. The central feature of the protocol is the induction of covalent crosslinks between protein and a directly bound (within ~1 Å) RNA by UV irradiation, which readily penetrates whole cells and even whole tissues. RNA-protein cross-linking is thus achieved without the addition of exogenous agents, such as photoactivatable reagents, or less selective chemical cross-linkers such as formaldehyde. In this way, endogenous protein-RNA interactions can be 'frozen' in vivo for subsequent capture by immunopurification. After cross-linking, RNA is partially hydrolyzed to reduce bound RNA fragments to 'footprint' sizes (typically ~30-50 nt) that can be cloned by RNA linker ligation and reverse-transcription (RT)-PCR amplification. When these PCR products are sequenced on a high-throughput platform, millions of unique RNA tags can be identified and mapped back to the genome, yielding unbiased transcriptome-wide RNA-protein binding maps.
Beyond the multitude of functions of conventional RNABPs in RNA regulation, the importance of miRNAs and related small regulatory RNAs in modulating gene expression is now firmly established. Mature, functional miRNAs are loaded in an obligate complex with Argonaute (Ago) proteins, which are the catalytic components of the RNA-induced silencing complex 1,2 . When complexed with Ago, miRNAs bind complementary base pairs in discrete mRNA target sites, primarily in 3′ untranslated regions, leading to silencing by translation repression or nucleolytic turnover 3 . miRNA:mRNA base pairing occurs chiefly within a short 'seed region' spanning nucleotides 2-8 of the 21-to 22-nt miRNA. As little as 6 bp of complementarity is sufficient for functional miRNA targeting, so that the number of potential miRNA target sites in the transcriptome (~1 in 4,000 nt for a 6-nt seed) far exceeds the number of functional sites. For example, given a cell that expresses 400 miRNAs, a 4,000-nt mRNA would be expected to bind to some miRNA once every 10 nt, far exceeding the observed frequency of ~2.3 Ago-miRNA binding sites per average transcript 4 . Indeed, although bioinformatic analyses have identified many miRNA targets, even the most rigorous efforts have had high rates of false-positive and falsenegative prediction [5] [6] [7] . Ago HITS-CLIP provides an empirical means to identify functional miRNA target sites by mapping the global transcriptome occupancy of Ago:miRNA:mRNA 'ternary' complexes in vivo.
Ago HITS-CLIP requires minor modifications of the standard protocol to accommodate Ago's association with two distinct RNA species: miRNAs and target mRNAs. Here, size selection by SDS-PAGE after immunopurification is especially crucial, as Ago:miRNA complexes run at a lower molecular weight (MW) (~110 kDa) than Ago:mRNA or Ago:miRNA:mRNA complexes (~130 kDa and higher). Parallel isolation and analysis of these populations yield two data sets: a transcriptome-wide map of Ago-binding footprints from the mRNA-enriched fraction (high MW) and an empirical catalog of functional, Ago-loaded miRNAs from the miRNA-enriched fraction (low MW). Interrogation of empirically determined Ago-binding sites for miRNA seed sequences provides a rational framework for the identification and validation of functional miRNA sites, with far lower false discovery rates (FDRs) than bioinformatic approaches alone 4 . Moreover, narrowing the sequence space of potential miRNA sites to bona fide Ago-binding footprints facilitates the discovery of unconventional miRNA:mRNA pairing rules, such as the recent discovery that ~15% of miR-124 sites in mouse brain possess a 'G-bulge' at position 5-6 that interrupts perfect complementarity 8 .
A final recent modification of HITS-CLIP analysis has capitalized on observations that reverse transcriptase is slightly error prone at the site of cross-linking [9] [10] [11] . CIMS can be used bioinformatically to map exact cross-linking sites, and hence RNAprotein interactions, with single-nucleotide resolution 10 .
Tissue cross-linking (Steps 1-3)
. UV cross-linking of cells and tissues is straightforward, and the suitable dose for a given sample tolerates some margin of flexibility. The starting material somewhat affects the cross-linking procedure, because excess UV irradiation can heat tissues and cause damage to RNA-protein complexes. Therefore, we typically apply less irradiation to tissue culture or primary cells in suspension or monolayer than to whole tissues such as brain. The original CLIP protocols irradiated freshly dissected tissue, either intact or triturated with a serological pipette. We have since observed excellent results by freezing samples in liquid nitrogen, grinding them with a mortar/pestle and keeping them frozen during UV irradiation. After irradiation, tissue can be frozen for long periods of time (years, in our experience). For initial experiments, a nonirradiated control sample is useful to assess polynucleotide kinase (PNK)-mediated labeling in the absence of cross-linking. In most cases, this control has little to no signal; however, there are some reported exceptions, including the tightly bound ~110-kDa Ago-miRNA complex, which is resistant to dissociation and therefore labeled even in the absence of cross-linking.
RNA digestion (Steps 10 and 11).
Reducing full-length RNA transcripts to footprint-sized fragments allows precise mapping of RNABP-binding sites after sequence tag alignment. Most CLIP studies have used limited digestion with RNase A, RNase T1, micrococcal nuclease, RNase I or combinations thereof 15 . Experimental titration of RNase is necessary to produce optimally sized RNA tags. The crucial control here is an overdigested sample, which should run near the predicted MW of the RNABP and provide a reference for the migration of partially digested experimental samples. In the case of Ago, two separate populations emerge at this stage: an ~110-kDa Ago-miRNA band and an ~130-kDa Ago-miRNA-mRNA band. Another useful control is an undigested sample, which indicates whether the input RNA is degraded.
Immunopurification of cross-linked RNABPs (Steps 13-17).
This crucial stage is likely to require the most troubleshooting and optimization, especially when prior immunopurification protocols do not exist for the antibody or RNABP of interest. It is beyond the scope of this protocol to teach IP technique, and the reader is referred to excellent manuals such as that by Harlow and Lane 47 and to a detailed discussion of these points in Green and Sambrook 48 . Some general points to consider include the following:
Antibody selection and optimization. In general, polyclonal antibodies have higher avidity than monoclonal antibodies, and they may be amenable to harsher wash conditions and hence better protein purifications. However, it bears mentioning that we have encountered considerable variability between lots for certain commercial polyclonal antibodies (e.g., Santa Cruz sc-10546, anti-Nova-2). Monoclonal antibodies offer the advantages of consistent performance and inexhaustible supply, but IP-competent monoclonal antibodies are unavailable for many proteins. Given the substantial background that may be evident with some antibodies, whenever possible we also recommend repeating CLIP with two different antibodies and comparing the results. Such technical replicates combined with biologic replicates generate 'gold-standard' HITS-CLIP data sets. IP/wash conditions. The most stringent IP/wash conditions that permit sufficient RNA recovery for sequencing will produce the 'cleanest' results. As a minimum, we recommend comparing IPs with moderate-stringency wash buffers (e.g., PXL, see below) and high-stringency wash buffers (high salt, low salt, high detergent and so on). We also recommend that, once wash conditions have been established, investigators titrate the amount of antibody to an amount just below the point of fully clearing the RNABP from supernatants. This strategy will balance high recovery with minimized background due to excess antibody. Controls. Important controls for this stage include nonspecific, isotype-matched antibodies for monoclonal antibodies or species-matched sera for polyclonal antibodies. In addition, samples depleted of the RNABP of interest (e.g., siRNA-transfected cells or tissue from null mutant animals) can be very useful in proving the specificity of signal in experimental samples 17, 22, 30 .
Labeling of RNA-protein complexes (Steps 21-24).
In this protocol, RNA-protein complexes are visualized by PNK radiolabeling. Direct labeling of RNA is most efficient, and it is suitable for most RNABPs examined. For Ago, direct PNK labeling produces high background signal, and it is inefficient for miRNAs, presumably because their 5′ end is buried in the protein interior 49 . Therefore, the alternative strategy of radiolabeling the 3′ RNA linker was adopted during Ago HITS-CLIP development 4 . An inconvenience of this approach is lower labeling efficiency, although this affects only the autoradiogram exposure time, and not the amount of retrievable RNA. Instructions for both direct PNK labeling and 
Size selection by SDS-PAGE (Steps 25-36).
Size selection of labeled RNABP:RNA complexes by SDS-PAGE is important for two reasons. First, this step visualizes the results of RNA digestion described above and thus allows isolation of RNA tags within an ideal size range. Second, SDS-PAGE separates the target RNABP from co-purifying contaminants, which may include other tightly associated RNABPs that survive the IP and washes or ones that cross-react with the antibody. For a number of RNABP/ antibody pairs, including Ago, we observe contaminant bands on SDS-PAGE of unknown identity that might compromise results if not removed at this stage.
RNA amplification (Steps 38-87).
After purification and extraction, RNA tags must be amplified and modified with adapter sequences compatible with sequencing. In published studies and the protocol below, amplification is achieved by standard ligation of RNA linkers followed by RT-PCR. The first key concern at this step is avoidance of overamplification, which will invariably favor predominance of certain PCR products and reduce sample complexity. We therefore go to substantial lengths to preserve sample complexity by empirically determining an optimal PCR amplification range for each sample. In the procedure described below, RT products from each sample are divided across eight PCRs. Four are run to different cycle numbers and analyzed by gel electrophoresis to determine an optimal cycle number. The remaining four are then run to the empirically determined cycle number and pooled for further processing. Other variations of this process are possible (as discussed previously 48 ). The attention paid to this point is at the discretion of the investigator, but in our hands even one unnecessary round of amplification can lead to a substantial drop in complexity (up to twofold per cycle). The second key concern at this step is avoidance of sample contamination. The most dangerous contaminants are adapter-bearing PCR products carried over from previous or parallel experiments. Such contaminants are highly stable on surfaces and in solutions, and their introduction at any point in the procedure can lead to false positive identification of RNABP-binding sites during analysis. A second source of contamination is RNA from any source introduced into samples before adapter ligation, which will be carried through in subsequent amplification. In the following protocol, we describe strategies to avoid and identify contamination, including the use of linkers with short nucleotide 'indexes' to mark samples and flag cross-contamination.
Overview of bioinformatic analysis. The bioinformatic analysis of HITS-CLIP data bears some conceptual similarity to the analysis of ChIP-seq data, which capture DNA-protein interactions 50 . However, HITS-CLIP data analysis has several distinct challenges owing to technical issues (e.g., UV vs. formaldehyde cross-linking) and biological variables (e.g., RNA-protein interactions are convoluted with the wide dynamic range of RNA abundance). Briefly, in the bioinformatic analysis of CLIP data, raw reads obtained from sequencers are first filtered to remove low-quality reads, and they are mapped back to the reference genome. Unambiguously mapped tags are then collapsed to remove potential PCR duplicates according to their genomic coordinates and to identify unique CLIP tags that represent independent captures of protein-RNA interactions. Removal of PCR duplicates mitigates the bias introduced by preferential PCR amplification of particular sequence tags. However, this step could also exclude some genuinely unique CLIP tags that have the same coordinates by chance (i.e., individual molecules with the same 5′ and 3′ ends, a particular issue when sequence-specific RNases such as RNase A are used). These possibilities can be distinguished by including a degenerate bar code in the ligated RNA linker (before PCR amplification). Tags mapping to identical genomic coordinates, but ligated to linkers with different degenerate bar codes, are likely to represent unique binding events, and thus they are retained. We have found that this strategy boosts the detection of unique tags by ~20% (C.Z., unpublished observations). Overlapping (or nearby, with relaxed stringency 25 ) unique CLIP tags are then clustered and ranked by the peak height (PH) of each cluster. As the observed PH is a function of both binding affinity and RNA abundance, there is still no straightforward way to infer quantitative binding affinity directly from CLIP data, in contrast to protein-DNA interaction analysis. Nevertheless, ranking of clusters by PH reflects robustness of signals. Several methods have been proposed to evaluate the statistical significance of PH above random backgrounds, although these methods differ in how gene expression level is normalized 4, 25 .
When CLIP experiments are performed with biological replicates, the data provide an opportunity to distinguish robust binding sites from those that are more transient or heterogeneous among individual samples. In addition to ranking clusters by PH, we typically filter clusters by requiring 'biological complexity', i.e., the presence of tags in all or a substantial fraction of biologically independent replicates 4,15,17,18,22 . Biological complexity reports on the presence or absence of tags in each replicate, and it does not take into account the exact number of CLIP tags in each experiment. A nonparametric meta-analysis integrating these metrics was recently described, but it is beyond the scope of the protocol here 22, 29 .
CLIP tag cluster and peak analysis typically determines the RNABP footprints on RNA transcripts at a resolution of 30-60 nt. Recently, we have exploited CIMS in HITS-CLIP data sets to map RNABP-binding sites at single-nucleotide resolution 10 . CIMS arise from the increased frequency (7-22%, depending on specific RNABP) of reverse transcriptase errors at the exact nucleotide where amino acids cross-link to RNA, which was initially observed in a small set of Nova CLIP tags obtained by Sanger sequencing 9 and then in the interaction sites of several snoRNAs or rRNAs with RNP proteins 11, 51, 52 .
To Table 1) . In both cases, cross-linking-induced substitutions appear more frequently than deletions, as judged from the number of robust CIMS and enrichment of motifs around CIMS. However, it is noteworthy that the identification of substitutions can be complicated by the existence of single-nucleotide polymorphisms, RNA-editing sites and other variables.
CIMS have been identified in diverse sequence contexts in patterns consistent with established binding specificities. For example, Nova and Hu predominantly cross-link to U in the YCAY tetramer and U stretches, respectively. In contrast, Ptbp2 predominantly cross-links to C of the UCUY motif, and Lin28 predominantly cross-links to G nucleotides. For Mbnl2, there also appears to be some difference in cross-link sites inferred from deletions and substitutions. Deletions occur in the last three nucleotides of the YGCY motif 34 ; substitutions mostly occur in the third position C (ref. 53 and C.Z., unpublished analysis of the data set from Charizanis et al. 34 ). As the exact nature and potential preferences of UV-induced protein-RNA cross-linking are not understood, we recommend that parallel analysis of all types of mutations be performed for new proteins.
For each type of mutations analyzed, CLIP tags are first clustered according to their genomic coordinates. Robust CIMS should be reproducibly supported by multiple CLIP tags, given sufficient sequencing depth. In contrast, mutations introduced by sequencing or alignment errors or other sources of noise should be randomly distributed. Therefore, statistical analysis can identify CIMS, which occur at a higher frequency than expected by chance. The two important parameters to measure robustness are the total number of tags overlapping each mutation site (k) and the number of tags with a particular type of mutation at the site (m). A permutation-based procedure can be used to evaluate whether the observation of m tags with mutations at a specific position is statistically significant above the background, given k tags that overlap with the position in total. In permutation, each mutation is planted into a randomly selected CLIP tag, with the same offset relative to the 5′ end of the read as observed in the original tag. Therefore, this permutation preserves the distribution of CLIP tags in the transcriptome, as well as the positional bias of sequencing errors observed in the Illumina platform. An empirical FDR is assigned to each mutation site on the basis of comparison of the two parameters k and m in real data and permuted data (see ref. 10 for more details).
To perform the tasks described here, a set of Perl scripts are used together with several standard Unix system tools in command line in the step-by-step protocol. For some steps, similar tools might be publicly available, and they can be used to replace the programs in this protocol (e.g., different sequence reads alignment programs, or C/C++ implementation of some of the steps to achieve faster speed). The focus of this computational protocol is to get a set of robust RNABP binding sites at a high resolution, starting from the raw data obtained from next-generation sequencing.
Downstream analysis
Downstream analysis of HITS-CLIP data will depend on the goals of the investigator and the specific factor being studied. Although largely beyond the scope of this protocol, the PROCEDURE includes steps to quantify binding peaks and to produce data tracks for visualization in the University of California, Santa Cruz (UCSC) Genome Browser 55 . The latter facilitates overlays with additional HITS-CLIP or other genome-wide data sets, such as RNA-seq expression data, conservation tracks and predicted regulatory motifs such as miRNA seed sites.
Software
Software and documentation on installation and use can be downloaded from http://zhanglab.c2b2.columbia.edu/index. php/CIMS. The software package is designed for Linux or other Unix-like operating systems, including Mac OS X. The software depends on several standard Unix tools such as sort, awk, uniq and cat, which are available in all common Unix-like operation systems. Some scripts also require Python, which is preinstalled in many linux releases and Mac OS X. If not, check http://www. python.org for more information. The program novoalign is used for read mapping; this software is available at http://www. novocraft.com. Basic familiarity with running command-line tools is assumed in this protocol. 
RNA linkers
Puromycin-blocked 3′ linker (with a 5′ phosphate): RL3: 5′-PGUGUCAGU CACUUCCAGCGG-3′-puromycin (Dharmacon; stored as a 20 µM, gelpurified and stored as described in Box 1). This is the standard 3′ RNA linker used for most RNABPs
Puromycin-blocked 3′ linker (lacking a 5′ phosphate): RL3(-P): 5′-OHGUG UCAGUCACUUCCAGCGG-3′-puromycin (Dharmacon; stored as a 20 µM, gel-purified and stored as described in Box 1). This linker is required only if the 3′ linker will be radiolabeled according to the protocol in Box 2 (recommended for Ago CLIP) RL5 RNA linker (Dharmacon; 20 µM stock, gel-purified and stored as described in Box 1) 5′-OHAGGGAGGACGAUGCGG-3′-OH RL5D RNA linker (Dharmacon; 20 µM stock, gel-purified and stored as described in Box 1) RL5D: 
Horizontal electrophoresis system (such as the Thermo Scientific Owl B1A EasyCast mini gel system) Access to high-throughput sequencing  crItIcal This protocol is designed for Illumina sequencing platforms. In the future, other platforms will require different primers. Microcentrifugal filter 0.45 µm (e.g., Pall Life Sciences, cat. no. ODM45C34) REAGENT SETUP Bead wash buffer (BWB) BWB contains 1× PBS (cell culture grade) and 0.02% (vol/vol) Tween-20.  crItIcal Unless noted otherwise, this and all of the following buffers can be prepared in advance and stored for several months at 4 °C. We prepare buffers by using nuclease-free salt and buffer stock solutions listed under Reagents section above; we bring them to the desired final volume with Milli-Q water and sterilize them with a 0.22-µM filtration unit. Detergents (Tween-20, NP-40/Igepal, sodium deoxycholate and SDS) are prepared first as 10% stock solutions in Milli-Q water and diluted appropriately for buffer preparation. Scrupulous care should be taken to avoid contamination with nucleases or nucleic acids. Periodic replacement of reagents (every 3-4 months) is good practice to ensure reagent quality. If contamination is observed in later PCR amplification steps, these reagents should be discarded and re-prepared. 
Box 1 | Gel purification of RNA linkers • tIMInG 4 h
We generally purify RNA linkers by denaturing polyacrylamide electrophoresis after receipt from the manufacturer. It is important that only full-length RNA linkers be included in ligation reactions (i.e., Steps 21 and 47), because the 5′ phosphate configuration and 3′-end blocking (with puromycin) ensure optimal efficiency. In addition, truncated linkers will complicate downstream bioinformatic analysis. Oligonucleotide manufacturers typically offer PAGE purification services, but in our hands the following protocol delivers far higher recovery. 1. Assemble a gel casting apparatus for a vertical electrophoresis system (e.g., Thermo Scientific Owl, P9DS-2 dual gel system) for a 1.5-mm-thick gel according to the manufacturer's instructions. 2. For each gel, mix the following in a 50-ml conical tube: RNA elution buffer RNA elution buffer contains 0.5 M ammonium acetate, 10 mM magnesium acetate and 1 mM EDTA. This buffer is stored at room temperature for up to 6 months. This reagent is used in Box 1.
Box 2 | 5′-end labeling of dephosphorylated RL3 linker • tIMInG 1 h
For some RNABPs, notably Ago, the signal-to-noise ratio for imaging labeled RNABP:protein complexes is improved by 32 P-labeling the 3′ linker before ligation, rather than by directly labeling the RNA with PNK. This procedure will yield enough 32 P-labeled RL3 linker for ten linker ligations reactions at Step 21A(i). Note that this protocol is unnecessary when direct PNK labeling (Steps 21B and 23B) is performed. 1. In an RNase-free 1.5-ml microfuge tube, add the following reagents in order:
10.5 µl RNase-free water 1 µl RNasin Plus 6 µl RL3(-P) linker ( Resuspend the cells in 8 ml of cold PBS and transfer them to a clean 10-cm dish. For fresh tissue, triturate or dice the tissues to create a gross suspension (small pieces of several mm 3 are fine) in ice-cold PBS. Transfer the tissue suspension to a 10-cm tissue culture dish and place it on ice. For frozen tissue, grind the tissue in liquid nitrogen to a fine powder with a mortar and pestle and transfer it to a Petri dish on a bed of dry ice.
2| Irradiate tissue culture cells or powdered tissue from
Step 1 once at 400 mJ cm 2 and then again at 200 mJ cm 2 in the UV cross-linker. Irradiate the triturated tissue three times at 400 mJ cm 2 in the UV cross-linker, by swirling between each irradiation to keep it cold and to maximize exposed surfaces for cross-linking. The Stratalinker or Spectrolinker cross-linkers have UV detectors that monitor the actual dose delivered. The units are labeled such that 1 = 0.1 J per m 2 ; hence, a setting of 4,000 on the machine is 400 mJ cm 2 .
3| Collect the cells into a 15-or 50-ml conical tube and pellet them by centrifugation at (200g for 5 min at 4°C). Remove the supernatant, resuspend the cell pellet in 1 ml of cold PBS and transfer it to a microcentrifuge tube. Re-pellet cells (~1,000g for 5 min at 4 °C in the microcentrifuge), remove the supernatant and freeze the packed cell pellets at −80 °C until use (each tube should have a maximum of 200-300 µl of packed cells or tissue). Alternatively, monolayer cells can be released with EDTA or scraped directly into lysis buffer and the centrifugations can be omitted.  pause poInt Cross-linked tissue can be used directly for lysis and IP, or it can be flash-frozen and stored at −80 °C for months to years.
Bead preparation • tIMInG 1 h 4| Pipette Dynabeads into an RNase-free 1.5-ml microcentrifuge tube. Place the tube in the magnet, allow the beads to collect on the side of the tube and remove the buffer. Wash the beads three times in BWB by using 1 ml each time.  crItIcal step The volume of Dynabeads per sample should be adjusted for the amount of antibody used. We assume a capacity of ~20 µg of IgG per 100 µl of Dynabeads. A minimum of 50 µl beads per sample is recommended to avoid loss during washes. The choice of protein A-versus protein G-conjugated beads depends on the species and/or isotype of antibody. Refer to the manufacturer's instructions for more details.
5|
Resuspend the beads in BWB and add the relevant antibody so that the final volume is the same as the original bead volume from Step 4. If applicable, also prepare irrelevant antibody controls, containing an equivalent amount of IgG as the anti-RNABP antibody.  crItIcal step As described in the Experimental design section, the amount of antibody will be different for each antibody-RNABP combination (according to antibody avidity, RNABP abundance and so on), and it needs to be determined in pilot experiments. For most antibodies, we conjugate directly to magnetic beads. As an example, for Nova CLIP from one P13 mouse brain cortex, we use 24 µg of goat anti-Nova2 antibody (C-16, sc-10546) with 200 µl of protein G Dynabeads. For Ago CLIP, we use the monoclonal antibody 2A8, which recognizes all four mammalian Ago proteins. We have found that 2A8 avidity is increased if it is coupled to DynaBeads via a 'bridging antibody.' For Ago CLIP from one P13 mouse brain cortex, we coat 200 µl of protein A-Dynabeads with 50 µg of rabbit anti-mouse IgG bridging antibody, according to Steps 4-7. We then wash away unbound bridging antibody with BWB, and then repeat Steps 4-7 with 4 µl of 2A8 anti-Ago ascites fluid. 2A8 and other anti-Ago antibodies are available from commercial sources (e.g., Millipore).
6| Rotate the tubes end over end at room temperature for 30 min (or overnight at 4 °C).
7| Wash the loaded beads three times with 1× PXL, 1 ml per wash. For these and all subsequent washes, ensure that beads are fully resuspended. After the final wash, leave the beads in a minimal volume of 1× PXL on ice until needed.
lysis, rnase digestion and Ip • tIMInG 3-4 h 8|
Resuspend the cross-linked tissue in each microcentrifuge tube with 1× PXL and incubate it on ice for 10 min. For crosslinked brain, suspend cell pellets in a volume of lysis buffer roughly three times the volume of packed tissue. If the tissue is resistant to lysis, gentle mechanical disruption (for example, with a Wheaton glass homogenizer) can be applied. For cell lysates from highly proliferative cultures such as some immortalized cell lines, sonication can be used to reduce viscosity due to high DNA concentrations if necessary.
9| Add 30 µl of RQ1 DNase to each tube. Incubate the tubes at 37 °C for 5 min at 1,000 r.p.m. in a Thermomixer.
10|
Make a 1:100 dilution of RNase A in 1× PXL and make three further tenfold serial dilutions (1:1,000; 1:10,000 and 1:100,000). As described in Experimental design, testing a range of RNase concentrations is important to determine a dose yielding optimally sized RNA fragments, as assessed by autoradiography (see ANTICIPATED RESULTS). The overdigested sample (1:100 dilution of RNase A) is a crucial control that will confirm cross-linking to protein of the appropriate molecular weight.  crItIcal step Optimal RNase concentrations vary markedly for different RNABPs and input materials. The concentration of lysate (i.e., mass of material per volume of lysis buffer) also substantially affects the rate of RNase digestion. Do not assume that RNase titrations performed in one source material (e.g., cell line or tissue) are valid for another, even for the same protein. The RNase dilution range specified above is deliberately broad; finer titration in future experiments can maximize the yield of appropriately sized RNA tags (see ANTICIPATED RESULTS and Fig. 2 ).
11|
For each RNase concentration to be tested, add 10 µl of diluted RNase per 1 ml of cross-linked lysate. Incubate the mixture at 37 °C for 5 min and transfer it to ice. After this step, lysates should be kept ice-cold to minimize further RNase digestion. An RNase inhibitor (e.g., RNAsin Plus at 0.2 U to 1 U per µl) can also be added to the lysates to quench RNase activity. Save an aliquot of the lysate (~10 µl) for subsequent immunoblotting (to confirm that your RNABP is not pelleted by the 32,000g clarification centrifugation described in Step 12).
12|
Centrifuge the lysates in a prechilled tabletop ultracentrifuge (in 11 × 34 mm polycarbonate tubes in a TLA120.2 rotor) at 32,000g (relative centrifugal force (RCF) avg ; e.g., 30,000 r.p.m. in the TLA120.2 rotor) for 20 min at 4 °C. This step can lead to a 'cleaner' IP for many proteins, particularly from tissue lysates, but it must be confirmed that the protein of interest is not lost in the pellet. Save a volume of 10-20 µl as both a postcentrifugation aliquot and a sample of the input to the IP for immunoblotting.
13|
Transfer the supernatant to the tube containing antibody-bound beads from Step 7.
14| Rotate the beads/lysate mix end over end for 1-2 h at 4 °C.
15|
Remove the supernatant and save 10-20 µl of the 'post-IP' aliquot for immunoblot analysis to confirm depletion of the target antigen from the lysate.
16|
Wash the beads with cold wash buffers. As described in Experimental design, pilot experiments should be done to determine the maximum stringency tolerated for post-IP washes and to test high-salt, low-salt and high-stringency (i.e., high ionic detergent) wash buffers. For Ago with 2A8 antibody, a standard wash protocol includes two or three washes with 1× PXL, followed by one or two washes each with high-salt, high-stringency and low-salt wash buffers (see Reagent Setup). The wash protocol used for Nova consists of three washes with 1× PXL wash buffer and one wash with 5× PXL wash buffer.
17|
Wash the beads twice with 1× PNK buffer.  pause poInt Cross-linked RNA-protein complexes are stable and can be left on washed beads in T4 PNK buffer overnight. Longer storage is not recommended, as there is risk of gradual dissociation of protein-antibody complexes (depending on the avidity of the antibody in use).
Dephosphorylation of rna tags
• tIMInG 1 h 18| Flash-spin the beads and remove residual PNK buffer. Resuspend the beads in dephosphorylation master mix thoroughly by gentle vortexing. A total reaction volume of 80 µl should be used for a starting volume of no more than 400 µl of Dynabeads. Here and for all subsequent enzymatic steps, volumes can be scaled down for smaller bead volumes, to a minimum volume of 40 µl. Prepare the dephosphorylation mix in an RNAse-free 1.5-ml microcentrifuge tube with the following components per sample:
RNase-free water 67 µl
Dephosphorylation buffer, 10× 8 µl
Alkaline phosphatase 3 µl
Optional: RNAsin Plus (Promega) 2 µl
19|
Incubate the reaction in a Thermomixer R at 37 °C for 20 min, shaking it at 1,000 r.p.m. for 15 s every 2 min.
20|
Wash the beads once with 1 ml of 1× PNK Buffer, once with 1 ml of 1× PNK+EGTA buffer and twice with 1 ml of 1× PNK buffer. Leave the beads on ice in a small volume of 1× PNK buffer until ready for the next step. (ii) Perform
3′ rna adapter ligation, on-bead
Step 21A(ii).
22|
Wash the beads once with 1× PNK buffer, once with high-salt wash buffer and twice with 1× PNK buffer. Leave the beads on ice in a small volume of 1× PNK buffer until ready for the next step.
5′ phosphorylation of rna tags
• tIMInG 1 h 23| Prepare a 5′ phosphorylation mix as follows: Use option A if
Step 21A was followed above, or use option B if
Step 21B was followed. (ii) Resuspend the beads thoroughly in 80 µl of phosphorylation mix, and incubate them in a Thermomixer R at 37 °C 20 min. Shake the beads at 1,000 r.p.m. for 15 s every 2 min. (iii) Add 1 µl of cold 10 mM ATP to each tube and incubate the mixture for an additional 5 min in a Thermomixer R at 37 °C, shaking it at 1,000 r.p.m. for 15 s every 2 min.  crItIcal step This 'cold chase' is crucial to ensure complete phosphorylation of RNA tags (and hence efficient 5′ linker ligation), as the total concentration of ATP in 32 P-γ-ATP preparations is very low.
24|
Wash the beads three times with 1 ml of 1× PNK+EGTA buffer. Leave the beads on ice in a small volume of buffer until it is ready for the next step. ! cautIon Washes will contain radioactive material that must be discarded appropriately.
sDs-paGe and nitrocellulose transfer • tIMInG 3-6 h 25| Flash-spin the beads and remove the residual buffer. Resuspend the beads in 1× LDS sample loading buffer prepared as follows (per lane of gel): 7.5 µl LDS sample buffer; 22.5 µl 1× PNK/EGTA buffer; optional (see below): 3 µl sample reducing buffer (Invitrogen) or 0.5M DTT.  crItIcal step Adjust the resuspension volume on the basis of how many gel lanes each sample will be divided across.
Overloading the gel lanes can result in distorted migration of samples owing to excessive IgG from IP antibody; a maximum of ~20 µg of IgG should be loaded in each lane. Similarly, the decision of whether to add reducing agent should be made to minimize interference from comigrating IgG bands. Reduced heavy and light chains of IgG run at ~55 and ~25 kDa, respectively, whereas nonreduced IgG runs at ~150 kDa. For Ago and other proteins running significantly higher than 55 kDa, we add the reducing agent. For RNABPs running below this range, such as Nova, the reducing agent is excluded.
26|
Incubate the mixture at 70 °C for 10 min, shaking it at 1,000 r.p.m. in a Thermomixer. ! cautIon The lower chamber running buffer will become radioactive from free 32 P-ATP.
29|
Transfer the gel to Protran BA-85 nitrocellulose by using a Criterion blot cell for 1 h at 90 V in 1× NuPAGE transfer buffer containing 10% (vol/vol) methanol, according to the manufacturer's instructions. ! cautIon Fiberglass 'sponges' become 'hot' during this step, and thus we reserve a set specifically for this purpose. Radioactivity in expended transfer buffer is negligible in our hands.
30|
Rinse the nitrocellulose filter in 1× PBS (RNase-free) and gently blot the edge on a Kimwipe.
31|
Wrap the nitrocellulose in plastic wrap, and then asymmetrically place two luminescent stickers on the plastic wrap so that the filter can be aligned with the film to excise the desired bands after exposure.
32|
Expose the filter to the film at −80 °C.
33|
Develop the film after 1-2 h and re-expose it if necessary for up to 3 d to see the 32 P-labeled complexes. Exposure times vary with input material, RNABP abundance and labeling method; direct labeling leads to a much higher signal than is seen with linker labeling. Tape or pin the plastic-wrapped filter to the film so that it cannot shift during excision.
36|
Identify the signal of interest ~20 kDa above the overdigested RNABP signal, using molecular weight markers as a guide. With a clean scalpel, excise a 5-10-kDa band of nitrocellulose centered on this signal. Transfer the nitrocellulose band to a clean surface with the tip of the scalpel. (The inside of an RNase-free pipette tip box lid is a convenient clean surface.) Use two scalpels to carefully dice each excised band into 1-to 2-mm squares, and then transfer these to an RNase-free, 1.5-ml microentrifuge tube.
Repeat these steps for each sample to be processed, by changing scalpels in between. For Ago, excise the bands from two gel regions: the region at ~110 kDa containing Ago:miRNA complexes and the smear above ~130 kDa containing Ago:miRNA: mRNA complexes. Paired miRNA and mRNA populations for each Ago sample will be processed in parallel for all subsequent steps (see ANTICIPATED RESULTS).
37| (Optional) As an analytical tool, run a separate western blot by using standard techniques 48 
42|
Centrifuge the tubes at full speed in a microcentrifuge (>12,000g for 10 min at room temperature) to separate the phases. Collect the aqueous (top) phase and transfer it to an RNase-free, 1.5-ml microcentrifuge tube.
43|
Add 0.5-1 µl of GlycoBlue and 40 µl of 3 M sodium acetate (pH 5.2) to the aqueous phase and vortex it. The glycogen is useful as a co-precipitant to precipitate small quantities of RNA; however, additional glycogen may inhibit T4 RNA ligase.
44| Add 1 ml of ethanol:isopropanol (1:1). Precipitate the RNA for 2 h to overnight at −20 °C.
5′ rna linker ligation
• tIMInG 3 h to overnight 45| Pellet RNA in a microcentrifuge at maximum speed (>12,000g at 4 °C) for at least 20 min. Remove and discard the supernatant as radioactive waste. Wash the pellet once or twice with 1 ml of 70% (vol/vol) ethanol, spinning it for 10 min each time to resolidify the RNA pellet.
46|
After removal of the final wash, spin the tubes for 1 min and remove the majority of residual ethanol. Evaporate the remaining ethanol by drying the pellet in a Speed-Vac, checking every 1-2 min to avoid overdrying. Alternatively, the pellets can be air-dried.
47|
Resuspend the RNA pellet in 5. 
49|
Add 100 µl of the DNase digestion mix to each sample and incubate at 37 °C for 20 min.
50| Dilute the sample with 300 µl of water, and then add 300 µl of RNA phenol and 130 µl of chloroform:isoamyl alcohol (24:1).
51|
Vortex the samples well and centrifuge them at maximum speed in the microcentrifuge for 5 min to separate the phases.
52|
Transfer the aqueous layer (upper phase) to an RNase-free, 1.5-ml microcentrifuge tube, and repeat the precipitation steps described in Steps 42-45.
reverse transcription • tIMInG 2 h 53| Resuspend the dried RNA pellets in 20 µl of RT-PCR-grade water. Divide each sample into two 10-µl aliquots in 0.2-ml PCR tubes, to be used for RT and a minus RT control ('−RT control').  crItIcal step In our experience, it is best to proceed from RT to PCR in the same day; storage of cDNA, even overnight, is not recommended.  crItIcal step The inclusion of a −RT control that lacks reverse transcriptase enzyme is the best way to evaluate contaminating DNA in CLIP samples. Such contamination can arise from very minute amounts of PCR products carried from previous or parallel experiments, and it can lead to false positive identification of RNABP-binding sites during analysis. The drawback is that splitting the RNA pool as described above will reduce sample complexity by half. As an alternative, we sometimes reserve a smaller fraction of RNA for the -RT control (e.g., 20%), and we adjust the PCR cycle number upward for -RT controls to compensate for lower input (see Steps 61-64). However, it should be noted that PCR product yield will not always scale linearly to cycle number in such a low range of cDNA input. Even so, the -RT controls will allow qualitative, if not quantitative, assessment of DNA contamination.
54|
To each sample, add 2 µl of DP3 primer (from a 5 µM stock) and 1 µl of 10 mM dNTPs.
55|
To anneal DP3 primer to the RNA, heat the tubes to 65 °C for 5 min and then cool them for at least 1 min on ice.
56|
In an RNase-free, 1.5-ml microcentrifuge tube, prepare a RT master mix containing the following components per RT sample. To prepare -RT control samples, replace the SuperScript III with nuclease-free water:
SuperScript FS buffer, 5× 4 µl
RNAsin Plus 1 µl
SuperScript III 1 µl 57| Add 7 µl of RT mix to each sample and mix it by pipetting up and down. Add 7 µl of -RT mix to -RT controls.
58|
Incubate the samples on a PCR block at 50 °C for 45 min, 55 °C for 15 min and 90 °C for 5 min, and finally hold it at 4 °C. Transfer the samples to ice.
pcr amplification • tIMInG 3-4 h 59|
In an RNase-free, 1.5-ml microcentrifuge tube, prepare the following PCR amplification mix for each RT sample (eight reactions in total; a master mix for 8.5 reactions is given to account for pipetting error). Divide this master mix into eight 0.2-ml PCR tubes, 30 µl each, on ice. 60| Prepare the following PCR amplification mix for each -RT sample (two reactions per -RT sample is sufficient to assess contamination, but more can be run if desired). Divide this master mix into two PCR tubes, 30 µl each, on ice.  crItIcal step Control reactions lacking template material (i.e., water or no-template controls) can also be useful to assess primer-dependent products in the PCR (e.g., primer dimers). We generally use the -RNA control described in Step 47 in place of template for this sample. This control is crucial when testing new primers, as the appearance of primer-dependent products in -RT controls may falsely indicate DNA contamination of input. 
61|

62|
Remove the four RT samples after completion of 20 PCR cycles and transfer them to ice. These samples are reserved for subsequent processing (see Step 73 below).  crItIcal step In our experience, one freeze-thaw cycle does not harm Accuprime polymerase performance. Reserved reactions can be stored at −20 °C before running additional PCR cycles.
63|
Remove one remaining RT sample after four different, subsequent cycles, separated by two or three cycles. analysis of pcr amplification products • tIMInG 6 h 65| Assemble a gel-casting apparatus for a vertical electrophoresis system (e.g., Thermo Scientific Owl, P9DS-2 dual gel system) for a 1.5-mm-thick gel according to the manufacturer's instructions. 69| Assemble the polymerized gels in the electrophoresis apparatus. Load the samples into wells, taking special care to avoid cross-contamination between different samples. Run the gel in 1× TBE running buffer at 350 V constant voltage for about 1 h until the bromophenol blue dye reaches the bottom of the gel.
70|
Disassemble the gel apparatus and immerse the gels in a 1:10,000 dilution of SYBR Gold in 1× TBE for 10 min with gentle shaking on a rotary shaker.
71|
Place the stained gel on a piece of plastic wrap and visualize the DNA with a transilluminator. Photograph the gel and return it to the buffer during examination.  crItIcal step Many transilluminators use 254-nm ulvtraviolet C (UVC) light, which can cause photonicking and photodimerization of PCR products. Use a 312-nm excitation wavelength to avoid this risk.
72|
Examine the gel images to evaluate the success of the experiment. The two key considerations are PCR product size and optimal PCR cycle number for each sample. miRNA-and mRNA-derived products should migrate differently at this stage: miRNAs as a distinct band at ~60 bp and mRNAs as a smear of ~80-120 bp. See ANTICIPATED RESULTS and Figure 3 for a detailed explanation of these points. ? trouBlesHootInG
73| Return the four reserved reactions from
Step 62 to the PCR block and run additional PCR cycles as in Step 61 to bring reactions to the optimal cycle number determined above (Step 72). . In each case, the 110-and >130-kDa complexes were processed separately after isolation of RNA from the nitrocellulose membrane. PCR cycle numbers for each reaction are indicated above the gel. DNA size markers are indicated in bp. White boxes indicate gel regions that were excised and processed for high-throughput sequencing, as described in ANTICIPATED RESULTS. The 'P' in a indicates primer-only products running below 50 bp, emphasizing the need for size selection and gel purification of appropriately sized products at this step. Primer-only products were run out of the gel in b. Note that for the 110-kDa complex, robust amplification of the ~60-bp miRNA-dependent product occurs at earlier PCR cycles than for the >130 kDa complex. Similarly, mRNA-dependent products, ideally a diffuse smear in the range from 85 to 110 bp, are enriched in the >130-kDa complex. There is substantial cross-contamination between these populations, the degree of which varies according to the resolution achieved at the SDS-PAGE step. However, we have found that separate, parallel isolation of these populations achieves higher complexity of mRNA tags, which represents a much more complex pool of sequences than the miRNA tags. Finally, note that products were excised from the lowest number of PCR cycles tested that gave a robust signal. Plateaued signal and upward shift in modal size are indications of overamplification. Overamplification of tags, even by one or two cycles, can substantially reduce tag complexity. 
79|
In an RNase-free, 1.5-ml microcentrifuge tube, prepare the following PCR amplification mix for each sample. Aliquot 30 µl of reaction mix into four 0.2-ml PCR tubes. 
83|
Load the samples on 3% (wt/vol) Metaphor agarose gel and run it in 1× TBE at 150 V for ~45 min. Visualize the stained gel on a UV transilluminator and photograph the gel.
84|
Excise the gel regions containing PCR products with a clean blade and transfer them to a clean 1.5-ml microcentrifuge tube. The SP5 and SP3 primers will add 57 bp to the products isolated at
Step 72 (see ANTICIPATED RESULTS).
? trouBlesHootInG 85| Isolate the DNA from the gel fragments with the QIAquick gel extraction kit according to the manufacturer's instructions. Elute the products in 30 µl of EB buffer.
86|
Quantify the DNA with a Quant-it DNA assay kit or another high-sensitivity method. Note that the concentration of DNA is usually low enough that quantification by λ 280 absorbance is not reliable. Before HITS, we also analyze sample quality and quantity on the Agilent TapeStation 2200 or a 2100 BioAnalyzer.
87| Submit the samples for HITS. Consult in advance with the facility about sample format and concentration. software installation and data retrieval • tIMInG 1 h 88| To install the software, download the CIMS software package (CIMS) and Perl library files (czplib) from http://zhanglab. c2b2.columbia.edu/index.php/CIMS and decompress the source codes in the home directory ('~/' per Unix convention). Here we assume that the compressed software package will be expanded into a folder 'src' with two subfolders 'CIMS' and 'czplib' under the home directory. Include the full path of the subdirectory 'src/czplib' in the perl library search path (e.g., by adding a line 'PERL5LIB=$HOME/src/czplib' in the file .bash_profile; this could vary slightly depending on the operating system).
89|
(Optional: first-time users) Download the sample data set, consisting of five independent Ago CLIP experiments on mouse cortex tissues, from http://ago.rockefeller.edu/rawdata.php (ref. 4) . mRNA tags from the 130-kDa band for brains D and E, comprising 6,259,297 and 6,394,071 36-nt raw reads, respectively, will be used in this protocol for demonstration. We assume that the two input files are located in the folder 'CIMS_demo' under your home directory, which is your working directory. These input files are in the fastq format, and each read has a unique ID, which is required by the software. Reads in this file do not contain a degenerate bar code and relatively few contain any 3′ linker sequence, and thus Steps 92 and 93 are skipped for this data set.
Filtering and pre-processing of raw reads • tIMInG 1 h-1 d 90|
Filter raw data according to quality scores. Low-quality reads can introduce mapping errors and background. They will inflate the number of unique tags after removal of PCR duplicates, especially when the complexity of a library is low.
In general, we require the average (mean) score of the first 25 positions (zero-based positions 0-24) to be ≥20 by using the following commands: The filtered reads will be saved in 'BrainD.fa' and 'BrainE.fa', respectively, in the fasta format. After filtering, 6,191,074 and 6,281,657 reads for brains D and E, respectively, will remain.  crItIcal step Historically, quality scores in fastq files were represented by numbers, which is the case for the two files used for this protocol. A more compact representation using ASCII characters with different offsets was later adopted. Illumina initially used offset 64 (i.e., Solexa fastq), but later switched to offset 33 (i.e., Sanger fastq), which is the default of this script for fastq files with encoded quality scores. Different encoding schemes can be specified by using the parameter '-if' . ? trouBlesHootInG 91| Collapse the exact sequence duplicates. If multiple reads have exactly the same sequence, only one is kept, and the copy number is attached to the sequence ID of the representative read:
perl ~/src/CIMS/fasta2collapse.pl -v BrainD.fa BrainD.c.fa perl ~/src/CIMS/fasta2collapse.pl -v BrainE.fa BrainE.c.fa A total of 1,325,922 and 1,341,563 reads will remain for brains D and E, respectively. As PCR amplification can produce a substantial number of sequence duplicates, this step will reduce the time for read alignment below (Step 94).
92|
(Optional: if sequenced fragments are likely to include substantial 3′ linker sequence) Trim 3′ linker sequence. The experimental protocol aims for RNA tag lengths of 50-100 nt. When Illumina read lengths exceed this fragment size, varying portions of the 3′ linker will be sequenced. When a substantial number of tags is expected to contain 3′ linker sequence, we recommend performing explicit 3′ adapter removal. This step will save substantial computing time during alignment (Step 94). For example, use the 'fastx_clipper' program in the software package 'fastx_toolkit' (http://hannonlab.cshl. edu/fastx_toolkit/) with parameters '-a GTGTCAGTCACTTCCAGCGG -l 15 -n' (note that this sequence matches the 3′ linker RL3).
Here we conservatively keep all reads ≥15 nt for downstream analysis. Note that this step should be skipped for the sample data set, because the reads are relatively short (36 nt) and will be aligned with iterative trimming (Step 94 below).
93| (Optional
codes, they should be removed and attached to the end of read ID, delimited by '#' (behind the copy number derived from Step 91). The exact command will depend on the structure of the CLIP library. In our design, the degenerate bar code (NNNNG) is present at the 3′ end of the RL5D 5′ linker, directly upstream of the actual CLIP tag sequences. We use the following command to separate the bar code from the rest of each read:
perl ~/src/CIMS/stripBarcode.pl -len 5 -format fasta sample.in.fa sample.out.fa
It may be necessary to adjust the sequence filtering step (Step 90), so that 25 nt of the actual CLIP tag sequences, in addition to the bar codes, are subject to filtering. Note that the sample data set does not have bar codes, and thus this step should be skipped.
read mapping and collapsing to obtain unique reads and mutations • tIMInG 1 d or more 94| Map reads to the reference genome (mm10). We use the program 'novoalign', which allows the detection of small insertions and deletions, in addition to substitutions. It also allows iterative trimming of the 3′ end of reads, which facilitates mapping of long reads that may run into the 3′ adapter or those with sequencing errors that prevent alignment of the full reads. Here mm10.idx is the indexed mouse genome generated by the tool supplied with the novoalign software (all 'chrN_random. fa' and 'chrM' files are excluded). The alignment cost score ('−t 85' here) controls the number of mismatches; one substitution costs 30, one deletion costs 55 and two consecutive deletions cost 70. Therefore, the argument -t 85 above allows two substitutions, two consecutive deletions or one substitution in addition to one deletion. It may be necessary to relax the threshold for longer reads. The option '−l 25' requires ≥25 high-quality matches. This parameter can be optimized on the basis of the specific application of the user; the default value of 25 was optimized empirically in our analysis of several RNABPs binding to mRNAs in mammalian genomes. The Native format is used for the alignment result file for historical reasons.
Other read mapping programs that allow detection of indels, such as bwa (http://bio-bwa.sourceforge.net/), can also be used, but they would require a different parser (not included in the package). It is also important to note that some of the mapping tools do not provide the option to perform read mapping with iterative trimming. In this case, it is critical to make sure that the adapter sequences are removed from the tag before alignment.  crItIcal step To minimize potential mapping errors, we require that each read maps to the genome unambiguously (no multiple hits). If multiple hits are allowed, it is important to assign a unique name to each hit in Step 95. To map RNABP interactions with transcripts known to have multiple copies or paralogs in the genome, such as some miRNAs, it is recommended to build a reference sequence database after redundancies are collapsed instead of using the whole genome as the reference for mapping. For instance, to identify Ago-miRNA interactions, we align CLIP tags against a fasta file containing all mature miRNA sequences. This strategy is generally recommended for mapping interactions with small RNAs (<25 nt) to avoid misalignment. Note that such mapping also requires adjusting the read length input for alignment and during initial filtering (Step 90).
95|
Parse the 'novoalign' output and save coordinates of unambiguously mapped tags and mutations detected in these tags in two separate files:
perl ~/src/CIMS/novoalign2bed.pl -v --mismatch-file BrainD.mutation.txt BrainD.novoalign BrainD.tag.bed perl ~/src/CIMS/novoalign2bed.pl -v --mismatch-file BrainE.mutation.txt BrainE.novoalign BrainE.tag.bed
The tag coordinate files ('BrainD.tag.bed' and 'BrainE.tag.bed') are in the BED format. The first six columns in the mutation files ('BrainD.mutation.txt' and 'BrainD.mutation.txt') contain information to create a BED file. Column 7 provides the zero-based position of each mutation relative to the chromosome start coordinate of the tag (i.e., the coordinate relative to the 5′ end for tags located on the positive strand, or relative to 3′ end for tags located on the negative strand). Column 8 specifies the nucleotide residue (A, C, T or G) at the putative CIMS on the positive strand of the reference genome (not necessarily the nucleotide in the sense strand). Column 9 provides the type of mutation ('>' for substitution; '-' for deletion ; '+' for insertion). Column 10 specifies the nucleotide residue at the putative CIMS on the mapped strand of the sequenced read. Column 11 is reserved. Column 7 is also duplicated in column 5. Note that mutations at the end of reads, typically owing to sequencing or alignment errors, are excluded in the output mutation files. For the sample data sets, 1,150,318 mutations in 1,044,927 unambiguously mapped tags were obtained for brain D. 1,150,318 mutations in 1,044,927 unambiguously mapped tags were obtained for brain E.  crItIcal step In the tag bed file, the 5′ column records the number of mismatches (substitutions) in each read, which might be required for Step 96.
96|
Collapse the potential PCR duplicates by coordinates and identify unique CLIP tags. PCR duplicates with sequencing errors will not have collapsed properly in Step 91. Two options are provided, depending on whether the 5′ linker contained a degenerate bar code: option A if reads lack degenerate bar codes at the 5′ end, or option B if the original reads contain degenerate bar codes: (a) If reads lack degenerate bar codes at the 5′ end (i) Collapse reads as follows:
perl ~/src/CIMS/tag2collapse.pl -v -weight --weight-in-name --keepmax-score --keep-tag-name BrainD.tag.bed BrainD.tag.uniq.bed perl ~/src/CIMS/tag2collapse.pl -v -weight --weight-in-name --keepmax-score --keep-tag-name BrainE.tag.bed BrainE.tag.uniq.bed
Among reads grouped for collapsing, the read with the largest copy number is retained because it is most likely to represent the original tag sequence before PCR amplification. Other variants, presumably arising from PCR and sequencing errors, are eliminated. Here we get 259,669 and 277,067 unique CLIP tags for samples D and E, respectively. If the input BED file is large (over ~6 million lines) and the script above complains of insufficient memory, the command line can be run with an additional option '-big' to avoid loading the whole file into the memory at the same time. This is also true for the following steps dealing with input bed files.
(B) If the original reads contain degenerate bar codes and this information was properly appended to the read IDs in step 93
(i) A more sophisticated probabilistic model is used to infer unique reads so that reads mapped to the same coordinates, but with sufficiently distinct bar-code sequences, can be retained as unique tags. Collapse reads as follows:
perl ~/src/CIMS/tag2collapse.pl -v --random-barcode -EM 30 --seqerror-model alignment-weight --weight-in-name --keep-max-score --keep-tag-name sample.tag.bed sample.tag.uniq.bed  crItIcal step This algorithm was described in detail previously 22 . Compared with the original algorithm, the current implementation allows sequencing errors in the degenerate bar codes to be estimated from results of read alignment, which is more accurate according to our simulations (C.Z., unpublished observations). Note that the read ID in the fourth column must take the form READ#x#NNNNN, where x is the number of exact duplicates and NNNNN is the bar-code nucleotide sequence (appended to read IDs in Steps 91 and 93, respectively). Read IDs that are not in this format will generate an error. In addition, the number of substitutions must be provided in the 5th column (derived in Step 95).  crItIcal step Collapsing PCR duplicates is crucial to mitigate bias introduced into HITS-CLIP experiments by extensive PCR amplification (see INTRODUCTION).
? trouBlesHootInG 97| Evaluate the strigency of filtering and sequence alignment. The best parameters for filtering raw reads (i.e., quality scores) and reference genome alignment (i.e., the number of mismatches allowed and the minimum length of matches) are not immediately clear in most situations and may need adjustment. In our experience, the fraction of unique tags over all mapped reads is of very informative value for diagnostic purposes. Incorrectly mapped reads (due to low quality in sequences or low-stringency mapping) will fall at random genomic positions and typically result in a higher fraction of unique tags. A useful diagnostic exercise is to partition all mapped reads into groups with respect to quality scores, matched size and other read mapping criteria, and to examine the fraction of unique tags in each group. If the protein of interest is known to bind predominantly to mRNA, another diagnostic measure is the fraction of intergenic or antisense tags, although extra caution is warranted here as some of these might be real biological interactions. The goal is to determine the thresholds ensuring that unique tags are not predominantly derived from low-quality sequences, or sequences with short matches and more mismatches. In general, a higher stringency of filtering and alignment is warranted for CLIP libraries with lower complexity to ensure higher signal to noise. In the sample data set, we did not see a substantial increase in the proportion of unique tags over all mapped reads as the size of sequence matches decreases, and a majority of unique tags were relatively long (i.e., 36 nt; Fig. 4 ).
98|
Prepare a bedGraph file of unique tags for visualization in genome browser. For simplicity, we combine the two samples together into a single track. However, one might want to visualize each individual experiment separately to make sure that all experiments work as expected, and to evaluate the reproducibility of biological replicates. Here we obtain 267,576 mutations, including 179,526 substitutions, 62,959 deletions and 25,091 insertions in 536,736 unique tags, which are used for further analysis below. The excess of deletions relative to insertions, which was not observed in RNA-seq data from non-cross-linked brain, is an indication that UV cross-linking specifically introduces deletions 10 . To support this conclusion, additional metrics such as the presence of miRNA target sites or RNABP motif sites for conventional RNABP CLIP must be examined (see below).
102| Separate different types of mutations:
awk '{if($9=="-") {print $0}' combine.tag.uniq.mutation.txt | cut -f 1-6 > combine.tag.uniq.del.bed awk '{if($9==">") {print $0}' combine.tag.uniq.mutation.txt | cut -f 1-6 > combine.tag.uniq.sub.bed awk '{if($9=="+") {print $0}' combine.tag.uniq.mutation.txt | cut -f 1-6 > combine.tag.uniq.ins.bed advised to use only the most robust CIMS (e.g., the top 1,000 sites) for de novo motif analysis. In addition, the removal of repetitive sequences (e.g., with RepeatMasker 57 ) is often helpful. For the sample Ago data set, a search for miRNA seed sequences is more appropriate (see Step 110). ? trouBlesHootInG 110| If you are performing Ago HITS-CLIP, search for miRNA seed matches around CIMS. This can be done by different tools, such as the 'fuzznuc' program in the 'emboss' package (http://emboss.sourceforge.net). Plot the frequency of seed matches relative to the position of the CIMS. Figure 6a shows the frequency of seed matches of mir-124, which is one of the most abundant miRNAs in the brain. ? trouBlesHootInG 111| (Optional) Separate analysis of CIMS with respect to the strand. Note that in Figure 6a , enrichment of miR-124 seed matches shows four peaks. Further examination shows that in this case deletions are frequently in the 5′ or 3′ end of the seed matches UGCCUU in the context of two or more uridines. In this case, it will be difficult to assign the deletion to a specific nucleotide in the U stretch. We can therefore examine CIMS on the two strands of the chromosome separately. (Fig. 6b,c) .
It is important to note that it remains a matter of debate whether the U stretch at cross-link sites observed for some RNABPs reflects an intrinsic bias toward cross-linking at U residues 10, 58 . We observed such U stretches enriched in the CLIP data of Hu/Elavl, Nova and Ago. However, these findings reflect established binding preferences for these RNABPs, and data sets for Mbnl2, Ptbp2 and Lin28 exhibited preferences at non-U residues (table 1). Nevertheless, it is advised that motifs uncovered by CIMS analysis (or any method) should be validated by independent biochemical and/or functional assays. ? trouBlesHootInG Troubleshooting advice can be found in The seed site match is located in a region with high-sequence conservation, as indicated by the 60-way phyloP conservation plot at the bottom of the panel 59 . Deletions occur in one of three uridines (bracket underneath the sequence) at the 5′ end of the seed site match where a robust CIMS was identified. For the latter, make sure the sequences of the sense strand obtained appears at ~110 kDa, regardless of RNase concentration. Ago:miRNA:mRNA ternary complexes run in a diffuse smear from ~130 to 150 kDa in partially digested samples (Fig. 2b) . The ideal result is a density of RNA labeling ~20 kDa above the size of the overdigested control. RNA should be extracted from this region of the nitrocellulose membrane (Fig. 2a) . The RNase dilution range specified in the protocol (Step 10) is deliberately broad, because optimal RNase levels vary widely for different RNABPs and source material. On the basis of initial experiments, careful RNase titration in a narrower range can maximize the signal corresponding to RNA tags of the desired size. For Ago, RNA should be isolated from two membrane regions: ~130-150 kDa to identify Ago:mRNA interactions and ~110 kDa to identify Ago:miRNA interactions. We process these samples separately, because miRNAs can be preferentially amplified at the expense of mRNA tags in subsequent steps owing to their smaller size and greater abundance in Ago IPs versus mRNAs.
The final point to evaluate is radiolabeled bands of unexpected size in the overdigested control. Contaminants may be unavoidable with certain antibodies, such as for 2A8 anti-Ago (Fig. 2b) , but they do not necessarily doom successful HITS-CLIP experiments. A potentially problematic source of extra bands is contaminating RNABPs that could confound downstream analysis (see ref. 6 for detailed discussion). This scenario is only of concern if a contaminating RNABP is of a size that interferes with selective retrieval of RNA cross-linked to the RNABP of interest. If contaminating bands are RNABPs, they should smear upward in partially digested samples relative to overdigested samples. In this case, the first possibility to consider is that the unexpected RNABP is an unknown isoform or degradation product (if smaller) of the RNABP of interest. If this is unlikely, it is usually possible to minimize contamination with undesired RNABPs by careful tweaking of experimental conditions, such as RNase levels, gel percentage or run time, or by adjusting the size range chosen for excision from the nitrocellulose membrane. There may be cases where complete separation of similarly sized RNABPs is impossible, but we have not yet encountered them. If labeled bands of unexpected size do not smear upward in partially digested samples, they are unlikely to be RNABPs and are therefore of no concern. Possible non-RNABP contaminants include DNA-binding proteins or kinases that autophosphorylate in the labeling mix.
sDs-paGe/western blotting (step 37)
Analysis of fractions collected at Steps 11, 12 and 15 by western blotting is useful to determine the success of RNABP immunopurification. This step is labeled 'optional' above, because we do not routinely perform this analysis for fully optimized protocols. However, in the development stages, this analysis is absolutely crucial. Comparing prespin (Step 11) and postspin (Step 12) fractions will confirm that the RNABP is not pelleted during the 32,000g spin. Most RNABPs will remain in the supernatant, but some large RNP complexes may sediment. If significant RNABP is lost at this stage, a lower-speed spin (e.g., in a microcentrifuge) should be used to clear the lysates of debris.
Comparison of postspin input (Step 12) with depleted IP supernatant (Step 15) will determine the extent of target depletion from the lysates. The goal should be depletion of a majority (>75%) of the RNABP from the lysates. Inefficient depletion raises the possibly that specific subpopulations (e.g., from specific complexes or cellular locations) will be preferentially isolated, leading to skewed RNA maps. If RNABP depletion is inefficient, the amount of antibody should be increased or IP conditions should be made less stringent. Conversely, total depletion of the RNABP is unnecessary, and in some regards it is not ideal. Total clearance of the RNABP could indicate that an excess of antibody is being used, which may lead to dirty immunopurifications. Our goal is usually titration of antibody to input material for 75-90% depletion of RNABP from lysates. Finally, robust target depletion with an unacceptably low autorad signal (Step 34) indicates that post-IP washes are too stringent or that the interaction does not survive the incubations for enzymatic steps (PNK or ligation). Antibody:antigen pairs are highly variable in their tolerance of detergent, high-salt and low-salt conditions. Wash conditions should be optimized in pilot experiments. However, if the antibody:antigen interaction cannot survive the enzymatic incubations, the antibody in unsuitable for this protocol. All of these parameters should be fully optimized before proceeding with isolation of RNA tags.
rt-pcr analysis (step 72)
The ultimate success of a HITS-CLIP experiment is determined by the ability to isolate and amplify RNA tags. RT-PCR results must be evaluated on three criteria: (i) the size and quality of PCR products, (ii) the optimal level of PCR amplification and (iii) evidence of sample contamination.
Product size and quality. For conventional RNABPs and the Ago:miRNA:mRNA complex, the ideal result of RT-PCR is a diffuse smear of appropriately sized PCR products in RT samples that is absent from -RT samples (Fig. 3) . Product size will depend on the region of nitrocellulose excised in Step 34 . An approximately 20-to 30-kDa shift for an RNABP by SDS-PAGE corresponds to cross-linked RNA tags of ~65-90 nt (including the 20-nt 3′ linker). These tags will, in turn, yield PCR products from ~85 to 110 bp (now including the 5′ linker). Smaller PCR products are acceptable, but as products get smaller, a greater number will fail to align uniquely to the genome during analysis. A diffuse smear pattern in this range is ideal; a 'bandy' pattern may indicate preferential amplification of specific products. In contrast, miRNAs are of uniform length (21-22 nt) and thus give rise to ~60-bp PCR products running as a single band. miRNAs are usually amplified at earlier PCR cycles than mRNA tags, and they are enriched in ~110 kDa Ago:miRNA complex (Fig. 2) . However, depending on the level of separation achieved by SDS-PAGE, mRNA tags are sometimes amplified from this region (Fig. 3) . Similarly, miRNA products are amplified from the ~130-to 150-kDa Ago:miRNA:mRNA region. Therefore, it is important to perform electrophoresis on PCR samples at Step 72 long enough to achieve a clear size separation of miRNA-and mRNA-derived products.
Optimal amplification. In determining optimal PCR cycle number, the goal is the lowest level of amplification yielding sufficient material to move forward (Fig. 3) . As a rule, if products are readily visible by eye upon UV illumination (i.e., without camera exposure), there is sufficient material to proceed. The integrated signal of PCR products at Step 72 should scale linearly with PCR cycle number; plateaued signal indicates that the PCR is outside the linear range and products are overamplified. Other indications of overamplification include a bandy pattern rather than a diffuse smear, or an upward size-shift relative to lower cycle numbers. Reactions within the linear PCR range, but with the lowest possible cycle number, should be purified at Steps 72-74.
Similar samples (e.g., biological replicates) should amplify in a similar range within and across experiments. However, because of low RT input and extensive processing, there may be some variability. For this reason, we empirically test a range of PCR cycles for each sample, even among replicates. As the protocol is optimized, it is likely that a finer range of PCR cycles can be tested and applied in future experiments. For example, Nova CLIP'd from ~100 mg of neonate mouse cortex typically has an optimal cycle number from 21 to 24 cycles. For Ago CLIP'd from similar material, miRNA tags will typically amplify between 24 and 26 cycles, whereas mRNA tags will amplify later, from 26 to 30 cycles.
Analysis for contamination.
The appearance of products in -RT control samples may indicate DNA contamination of samples or reagents. Of particular concern are products that 'look like' those appearing in the RT samples (i.e., similar size and, most ominously, in a similar amplification range). If such products appear in a -RT control sample, we recommend abandoning the corresponding RT sample. Importantly, not all forms of contamination can be identified at this stage. Only adapter-containing DNA contaminants, introduced by sample cross-contamination or carry-over from prior experiments, will give products in a -RT control. A more general discussion of contamination appears below. Important points to consider in interpreting -RT controls include the following:
To properly compare RT and -RT samples, it is essential to examine reactions that have undergone similar amplification. If RNA was evenly divided between RT and -RT samples at Step 53, reactions of the same cycle number can be compared directly. If less RNA was used in -RT samples, PCR cycles must be adjusted upward accordingly for a fair comparison. For example, if 80% of RNA was used for RT and 20% for -RT, -RT reactions should be run for two additional cycles to compare fairly to corresponding RT reactions. This is not a fully justified assumption, because PCR will not always scale linearly with very low amounts of input material. Therefore, we often examine -RT reactions several cycles beyond the range tested for RT samples when input RNA is divided unevenly. If products appear only at late PCR cycles in -RT controls, it could indicate low levels of DNA contamination. The decision to move forward in this case is at the discretion of the investigator. A gap of 10 cycles between RT and -RT samples (indicating 1 in every 2 10 , or 0.1% contamination) will be acceptable in many circumstances, whereas a gap of three or four cycles is far more worrisome. Given the expense and time required to produce and analyze HITS results, we exercise extreme caution in making these judgments. It is possible for primer-dependent products to appear in -RT controls, sometimes as a primer-dimer or ladder. These products do not doom the experiment as long as they are absent from RT samples. If you suspect primer-dependent products, this can be confirmed by TOPO-TA cloning and standard DNA sequencing. We speculate, but cannot prove, that such primer-dependent products are sometimes more favored in the absence of template. A no-template control (see Step 60) can be helpful in identifying primer-dependent bands. The results of the second PCR to add sequencing adapters should be evaluated to confirm correct product size and to determine optimal amplification. Contamination at this stage is a lesser concern than above, because the input material is far more abundant and requires less PCR amplification. Adapter sequences in primers SP5 and SP3 are 36 and 21 nt, respectively, adding a total of 57 bp to the products isolated at Step 72. Products in the range of 80-120 bp will therefore yield a smear from ~147 to 177 bp here. As in Step 72, isolate the lowest cycle-number reactions with adequate product to proceed. Generally, products readily visible by eye upon UV illumination (i.e., without prolonged camera exposure) will yield sufficient material after gel purification for sequencing. In practice, it may be helpful to isolate products from two or more reactions and to proceed with the least-amplified sample with sufficient yield. Consult your sequencing facility in
• •
• determining the amount of product that is required for analysis. As in the first PCR, plateaued signal, a bandy pattern rather than a diffuse smear or an upward size-shift relative to lower cycle numbers are signs of overamplification that should be avoided.
contamination of samples
Unfortunately, HITS-CLIP and other adapter-mediated PCR protocols are highly vulnerable to contamination because even vanishingly minute amounts of contaminants can be efficiently amplified. As a general measure, scrupulous attention to reagent quality is essential. To this end, we frequently replace inexpensive reagents (e.g., ethanol, IP buffers and water), and we make aliquots of more expensive reagents (e.g., enzyme buffers, dNTPs, primers) for single use. In addition, pipette tips with aerosol filters should be used at all stages. Finally, equipment such as gel apparatuses that contact adaptercontaining DNA or RNA should be decontaminated regularly with diluted bleach. Two major types of contaminants are most common: adapter-containing DNA products, introduced at any stage and undesired sources of RNA, introduced at any stage before RT.
DNA contaminants. DNA contaminants are likely to arise from cross-contamination between samples or carry-over from prior experiments. These contaminants can be introduced at any stage before PCR, and they are especially dangerous because of their inherent stability on surfaces and elsewhere. The DNase treatment at Step 49, after 5′ linker ligation, is meant to destroy potential DNA contaminants before RT-PCR. In addition, analysis of -RT controls is intended to diagnose DNA contamination.
RNA contaminants. RNA contaminants can take several forms. Accidental introduction of any RNA before linker ligation will lead to false identification of cross-linked RNA tags. In addition, cross-contamination or carry-over of linker-containing RNAs can occur at any stage before RT, with the same result. These forms of contamination cannot be identified with -RT controls. As a countermeasure to this form of contamination, we have begun to use 5′ RNA linkers containing short 2-to 3-nt indexes to uniquely identify samples. An example of our 5′ linker RL5D, which contains a dinucleotide 'CA' index, follows: 5′-OHAGGG AGGACGAUGCGGCAr(N)r(N) r(N)r(N)G-3′-OH.
Note that this 'index' is distinct from the degenerate bar codes in the 5′ linker used to collapse PCR duplicates. We rotate the use of different indexed 5′ linkers, so that cross-contaminants can be easily filtered during bioinformatic analysis. This strategy has the added benefit of allowing multiplexed sequencing analysis of samples. However, this measure will not identify contaminants introduced before 5′ linker ligation (Step 47). It is less straightforward to incorporate indexes into the 3′ linker, because, for many tags, sequencing will not reach the 3′ end owing to variable tag length. Use of a pair-end sequencing strategy would make the use of indexed 3′ linkers possible, but it is more expensive and would require re-design of the adapter sequences described here.
In addition to spurious sources of RNA contamination, experimental sources such as co-purifying RNABPs are possible culprits. Instructions for the diagnosis and treatment of these contaminants are described in ANTICIPATED RESULTS for SDS-PAGE/autorad results.
